Johnson & Johnson, of New Brunswick, N.J., said new data for its Xarelto (rivaroxaban), published in the October issue of Thrombosis Research, show reduced risk of recurrent venous thromboembolism in morbidly obese patients, with effectiveness and safety similar to warfarin. Read More
Curamir Therapeutics Inc., of Woburn, Mass., was launched by Delos Capital, with a $10 million series A financing to support work on micro RNA-based cancer therapeutics. Read More
San Diego-based Exagen Diagnostics Inc. has a somewhat unique business model. It's aiming to both improve diagnostics and monitoring for autoimmune patients, but also to partner with biopharmas to promote better testing – and even to market related therapeutics to autoimmune specialists. Read More
HONG KONG – South Korea biotech venture Spark Biopharma Inc., based in Seoul, has secured KRW25 billion (US$21 million) in series B funding for new drug pipeline R&D. Read More
Looking at human tissues has given British researchers a new window into the relationship between adipose tissue and disease cardiovascular disease risk. Read More
During its second-quarter earnings report, Cambridge, Mass.-based TCR2 Therapeutics Inc. touted the start of a phase I/II trial with TC-210 to treat patients with mesothelin-positive tumors of various types, and interest continues to grow in the company's approach. Read More
Gaba Therapeutics Inc., of Newport Beach, Calif., closed on a series A of up to $15.5 million to create a new compound for treating mood disorders, particularly anxiety and depression. Read More
Bagsvaerd, Denmark-based Novo Nordisk A/S' chief medical officer, Todd Hobbs, told BioWorld it "won't be too much longer" – probably a week or so – before the firm sets pricing of oral once-daily Rybelsus (semaglutide) in type 2 diabetes, approved Friday thanks to a priority review voucher that guaranteed a greased path for the first non-injected glucagon-like peptide (GLP-1) receptor protein therapy. Read More
Seeking to address a rising tide of retinal disease, Boehringer Ingelheim GmbH has agreed to pay Newton, Mass.-based Inflammasome Therapeutics Inc. as much as $160 million for rights to use its intravitreal drug delivery technology with up to three Boehringer compounds. Read More
Scientists at the University of Freiburg have shown that antibody-based prophylactic treatment after bone marrow transplant (BMT) could prevent infections without reducing the diversity of the gut microbiome. BMT is a cure for a number of blood cancers, but it has a very high complication and death rate itself. Read More
